Medarex reports promising Ph I data on HL drug
US drugmaker Medarex reported encouraging preliminary data from an ongoing Phase I trial of MDX-1401 in patients with relapsed or refractory Hodgkin's lymphoma at the annual meeting of the American Association for Cancer Research in Denver, Colorado.
The agent demonstrated both clinical and immunological activity signals. MDX-1401 is a fully-human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers.
"We find these preliminary safety and efficacy data for our second-generation, anti-CD30 antibody encouraging," said Geoffrey Nichol, senior vice president of product development at Medarex. "We are currently enrolling additional patients at higher dose levels and look forward to examining further results from the ongoing Phase I trial," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze